Different factors influence delay in breast cancer treatment for African-American and white women

The delay between diagnosis and first course of treatment for breast cancer is influenced by different factors for African-American and white women.

Using data from the Caroline Breast Cancer Study (CBCS) Phase III, scientists found that, among white women, household size and losing a job due to one's diagnosis were reasons for delay in treatment. Among African-American women, the type of treatment influenced delay.

Both African-American and white women experienced delay if they underwent immediate breast reconstruction following mastectomy. Notably, African-American women were more likely (92.5%) than white women (60.6%) to experience delay associated with this procedure.

This study was published in Cancer Epidemiology, Biomarkers & Prevention (2013; doi: 10.1158/1055-9965.EPI-12-1432). The researchers categorized women into two groups: those who received treatment within 30 days of diagnosis, and those whose treatment was delayed by more than 30 days.

"Our goal was to identify the factors that contribute to treatment delay and to assess whether disparities in delay exist between African-American and white women," said Sasha McGee, PhD, an epidemiology graduate student at the University of North Carolina Gillings School of Global Public Health in Chapel Hill at the time of this study.

The study found that African-American women between the ages of 20 and 49 were more than three times as likely as white women in this age range to experience treatment delay.

"The study results suggest that specific populations of women need to be targeted when characterizing and addressing determinants of treatment delay, and that younger African-American women may benefit from interventions to reduce disparities in treatment delay," said McGee.

The study population consisted of 601 women with breast cancer between the ages of 20 and 74 who were enrolled in the CBCS between 2008 and 2010. The CBCS is an ongoing population-based study that recruits women from 44 counties in North Carolina.

"We used information from interviews and questionnaires to collect socioeconomic data for each woman," McGee added. "Larger studies often use area-level information for groups of people [eg, census data] and apply these data to individuals in the study, which may not always be accurate." Clinical and treatment information were obtained by reviewing the medical records for each study participant.

"One of the goals of the CBCS Phase III is to assess five- and ten-year survival for study participants once recruitment ends in 2014. Follow-up interviews for study participants will continue for up to five years after diagnosis, therefore not only will we be able to evaluate the impact of a treatment delay of more than 30 days on survival, but also the impact of barriers to treatment and healthcare access," said McGee.
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs